Press Releases

BIA welcomes Minister’s Reassurance on the Patents (Amendment) (EU Exit) Regulations 2018

The Government last night committed to further consultation with the BIA on the UK’s future Intellectual Property rights regime in the event of a ‘no deal’ Brexit following concerns raised in the House of Lords. 

2018 a record year for UK biotech fundraising

New figures published today (Thursday 24 January 2019) by the UK BioIndustry Association (BIA) and Informa Pharma Intelligence reveal that the UK biotech sector raised a record £2.2 billion from investors in 2018. The total is the best ever recorded by the trade association and almost double that raised in 2017. The data is presented in the report Confident capital: backing UK biotech and launched by the Exchequer Secretary to the Treasury, Robert Jenrick MP, at the BIA's Strategic Technologies event in central London today.

BIA response to Health Secretary's plan to contain and control AMR

Steve Bates OBE, CEO of the BIA said:  “It’s great to see the UK government and NHS committed to exploring a new payment model for antibiotics in our market. The UK took a lead in putting Anti Microbial Resistance (AMR) on the global agenda and it’s really good to see it taking a first mover advantage on innovative pricing and reimbursement for AMR. 

BIA welcomes the announcement of Nicola Blackwood as new Under-Secretary of State for Health

The BIA welcomes the announcement of Nicola Blackwood as new Parliamentary Under-Secretary of State for Health. BIA CEO, Steve Bates OBE, said: “As a former health minister and former chair of the science and technology committee, and serving as a board member of Eagle Genomics, Nicola knows our sector well and is well-placed to hit the ground running. We had a strong relationship with Nicola when she was minister for health, and we look forward to working with her to ensure the UK stays a world-leader in the life sciences.”


Member News

Discovery Park announces Chris Broom as Head of Business Development

New appointment is key part of delivering science park’s ambitious plans for growth

Babraham Bioscience Technologies announce new Board Member

The Board of Babraham Bioscience Technologies (BBT), which develops and manages the Babraham Research Campus, welcomes Dr Karen Lewis, as Non-Executive Director.

PRESS RELEASE First production and administration of Axumin® (fluciclovine (18F)) in Italy

Oxford, UK – February 12, 2019 – Blue Earth Diagnostics, a leading molecular imaging diagnostics company, today announced that the first commercial production of Axumin® (fluciclovine (18F)) in Italy occurred recently, with the first Italian patients being dosed.

Super-Fast-Acting Prandial Insulin Product Receives £0.5M Innovate UK Boost

Super-fast product addresses critical unmet need in development of next generation artificial pancreas systems” “Novel formulation significantly accelerates absorption of insulin post injection - accelerating the onset of glucose lowering.”


BIA blog

Video of the Week | Unravelling How The Brain Works | Wellcome Trust

One of the key policy areas of focus for the BIA is pre-clinical research. The use of animals is a key part of research in the safe and efficient development of medicines, and is a legal obligation for researchers. The BIA are signatories of the Concordat on Openness on the Use of Animals in Research, an agreement which promotes transparency and understanding of animals in research. Good science and good animal welfare go hand-in-hand, and this video from the Wellcome Trust highlights just how important the use of animals is when researchers seek to unravel the complexities of disease and human biology.

Preparing for the Spending Review | Part 2: Bringing key messages to Parliament 

A key part of the BIA’s work on the Spending Review (SR) is engaging parliamentarians, who have a role in scrutinising and approving the Government’s decisions. To start this process, two weeks ago we teamed up with partner organisations across the life sciences sector to organise an event in the House of Commons – “Keeping the UK a world leader in medical research: the need for cross-government coordination”.

CEO Update | Monday 18 February 2019

BIA Chair Jane Osbourn has announced this week that she is to leave Astra Zeneca after 25 years with Cambridge Antibody Technology and MedImmune. During that time she has achieved a huge amount of biological drug development, with 8 drugs launched, and biologics now making up 50% of the AZ pipeline. Jane will help with organisational transition at AZ for the next few months and has assured the BIA Board that she will continue as BIA Chair until the end of her term. Jane’s news follows AZ’s announcement (alongside their annual results last week) that it will be restructuring the R&D organisation to align with therapy areas.

BIA launches new Brexit Microsite

We are delighted to launch our very own Brexit microsite today. The microsite shows the important work that the BIA has done in this crucial area and highlights the issues that matter most to our members.


Our publications

Please find a selection of featured BIA publications below. To see our full publications library, click here

Influencing and shaping our sector, BIA update: January - April 2018

This quarterly update gives an overview of key policy developments and the BIA’s continued engagement with policymakers, regulatory authorities and wider stakeholders on behalf of the UK life sciences industry, from January to April 2018.

Biotech Financing Update: December 2017 to February 2018

The BIA/Informa Biotech Financing Update: December 2017-February 2018 released today shows that venture capital financing and follow on financing on the public markets are off to a solid start in 2018.

Pipeline Progressing: The UK's Global Bioscience Cluster in 2017

A new report released by the BioIndustry Association (BIA) and Informa Pharma Intelligence reveals that the UK has the strongest clinical and preclinical pipeline in Europe.

BIA Best practice guide for communicating R&D

Ensuring investors and the wider public are well informed and confident about bioscience is crucial to the success of individual companies and the sector as a whole. To support the sector to maintain high standards in communications about R&D progress, the BIA has produced a best practice guide for bioscience companies with a supporting library of resources.